LDLR and Hepatic steatosis: In a 12-weeks intervention, fenofibrate (50 mg/kg/d) elevates plasma level of TG as well as liver steatosis in ob/ob and low-density lipoprotein (LDL) receptor (LDLR)-double deficient mouse, a model of obesity and hyperlipidemia (21).